4th edition speakers

Nobel Laureate Prof. Harald zur Hausen

Nobel Laureate Prof. Harald zur Hausen

Senior Scientific Consultant, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
Research Group Episomal-Persistent DNA in Cancer- and Chronic Diseases

PLENARY LECTURE

Epidemiology and links of bovine meat and milk factors (BMMFs) and their role in human cancers

Biography

Harald zur Hausen was born on March 11, 1936 in Gelsenkirchen-Buer, Germany. He studied Medicine at the Universities of Bonn, Hamburg and Düsseldorf and received his M.D. in 1960. After his internship he received the license to practice medicine and worked as a postdoc at the Institute of Microbiology in Düsseldorf, subsequently in the Virus Laboratories of the Children’s Hospital in Philadelphia where he was later appointed as Assistant Professor. After a period of 3 years as a senior scientist at the Institute of Virology of the University of Würzburg, he was appointed in 1972 as Chairman and Professor of Virology at the University of Erlangen-Nürnberg. In 1977 he moved to a similar position to the University of Freiburg. From 1983 until 2003 he was appointed as Scientific Director of the Deutsches Krebsforschungszentrum (German Cancer Research Center) in Heidelberg. He retired from this position in 2003.

He received a number of national and international awards, among them the Robert-Koch-Price, the Charles S. Mott Price of the General Motors Cancer Research Foundaton, the Federation of the European Cancer Societies Clinical Research Award, the Paul-Ehrlich-Ludwig Darmstädter-Price, the Jung-Price, Hamburg, the Charles Rudolphe Brupbacher Price, Zürich, the Prince Mahidol Award, Bangkok, the Raymond Bourgine Award, Paris, the Coley-Award, New York, the Life Science Achievement Award of the American Association for Cancer Research, San Diego, and the Nobel-Prize for Medicine, 2008.

Prof. Ethel-Michele de Villiers

Prof. Ethel-Michele de Villiers

Senior Scientific Consultant, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
Research Group Episomal-Persistent DNA in Cancer- and Chronic Diseases

PLENARY LECTURE

A novel class of infectious agents linked to colon, breast and prostate cancers. Characterization of the respective agents 

Biography

Ethel-Michele de Villiers is a biologist. She researches the viral causes of cancer at the DKFZ in Heidelberg.

De Villiers graduated from school in Pretoria in 1965 and studied biology at the University of Pretoria. She received her doctorate (D. Sc.) In 1980, went to the Albert-Ludwigs-Universität Freiburg and then to the Veterinary Institute Onderstepoort in South Africa. From 1984 she worked at the DKFZ.

She identified many new types of papillomavirus and studied their role in causing cancer. From 2000 she works on the identification and analysis of the Torque Teno Virus (TTV). In addition, she deals with the similarly structured but genetically different Bovine Meat and Milk Factors (BMMFs) which, according to zur Hausen and Villiers, play a role in colon cancer and breast cancer.

Prof. Olli Tenovuo

Prof. Olli Tenovuo

Pathophysiology, diagnostics, treatment, and prognosis of traumatic brain injury

KEYNOTE SPEAKER

Biomarkers of traumatic brain injury – the biggest challenge of brain biomarker diagnostics?

Traumatic brain injury (TBI) is a major public health concern, with an estimated 50 million new victims annually worldwide and costs possibly exceeding 500 billion € per year in Europe alone. TBI has been said as man’s most complex disease in man’s most complex organ. In this presentation I will point out the current major problems in TBI diagnostics, highlighting the vast need for reliable biomarker diagnostics. I will also go through the problems in developing biomarkers for clinical use in TBI, because of which the use is still negligible despite vast amount of research. Finally, I will give an overview on the current state of the field and the expected future views.

Biography

Olli Tenovuo is a Professor of Neurotraumatology at the University of Turku and the Head of the Turku Brain Injury Center at the Turku University Hospital. He has led a multidisciplinary TBI research group since 1996 and published > 150 peer-reviewed papers on TBI. His research has focused in developing new diagnostic tools for TBI, and in clarifying the pathophysiological mechanisms of human TBI. He has participated in several international research efforts on TBI and been an active member in international TBI societies and expert groups. He has combined clinical research with the clinical care of patients with TBI throughout his career, giving a strong clinical background for the research efforts.

Selected publications:

  • The levels of GFAP and UCH-L1 during the first week after a traumatic brain injury: correlations with clinical and imaging findings. Neurosurgery 2016;79:456-64.
  • Human serum metabolites associate with severity and patient outcomes in traumatic brain injury. EBioMedicine 2016;12:118-26.
  • Serum metabolites associate with CT findings following TBI. Journal of Neurotrauma 2018;35:2673-83.
  • Early levels of GFAP and NF-L in predicting the outcome of mild TBI. Journal of Neurotrauma 2019;36:1551-60.
  • Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study. EBioMedicine 2020;56:102785.

Our speakers are subject to change and reflect the current situation (20.08.2020). Stay tuned for further information by registering to our newsletter.